HNGE
Hinge Health, Inc.
Last earnings +1.8% on 2026-05-05
$78.97
▲ +5.10%$78.97▲ +87.71%
over 1Y
L $31.17EODHDH $78.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.1%
1W+14.7%
1M+47.4%
3M+117.8%
YTD+73.3%
1Y+87.7%
Hold
Conviction
Horizon
Long (>12mo)
Street · 22 analysts
Buy
Digital MSK leader growing 51% with 80% gross margins and positive cash flow — the giant GAAP loss is an IPO stock-comp artifact, not distress.
Hinge Health is a digital musculoskeletal (MSK) care platform that uses AI-powered motion tracking (TrueMotion), a nerve-stimulation wearable, and an AI-supported care team to deliver scalable joint-and-muscle care to self-insured employers and health plans. FY2025 growth was strong — revenue rose 50.6% to $588M with gross profit up 56.1% and an excellent 79.6% gross margin — extending a rapid ramp from $293M in FY2023. The platform is sticky: clients sign ~3-year contracts with Hinge typically the sole digital MSK provider, and the company has 60+ partners including the five largest national health plans by self-insured lives and the top three PBMs.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $293M | $390M | $588M |
| Gross profit | $194M | $300M | $468M |
| Operating income | -$131M | -$31.9M | -$546M |
| Net income | -$108M | -$11.9M | -$528M |
| Diluted EPS | -$8.31 | -$0.88 | -$7.77 |
| Net margin | -36.9% | -3.1% | -89.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)-241.6%
Free cash flow$171M
Total debt—
Net cash$208M
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-162026-06-18open ↗144Filing2026-06-16open ↗144Filing2026-06-16open ↗144Filing2026-06-16open ↗144Filing2026-06-16open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-092026-06-09open ↗SCHEDULE 13G/AFiling2026-06-08open ↗4Period ending 2026-06-052026-06-05open ↗
Frequently asked
- Is Hinge Health, Inc. (HNGE) a buy?
- HNGE currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Digital MSK leader growing 51% with 80% gross margins and positive cash flow — the giant GAAP loss is an IPO stock-comp artifact, not distress.
- What is Hinge Health, Inc.'s quality score?
- HNGE scores 42.43589743589744/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001673743, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 9:01:09 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.